China’s National Reimbursement Drug List (NRDL)
What is NRDL? The National Reimbursement Drug List (NRDL) was introduced in 2000 to support medical healthcare and providing patients with basic medical treatments. Between 2000 and 2017, the NRDL has been updated twice, but the reimbursement process is poor. The...
China Introduces Structural Changes to Pharmaceutical Regulations
Beginning of Changes China revised its pharmaceutical regulations by releasing the second draft of the Drug Administration Law of the People's Republic of China (DAL) to the Committee of the National People's Congress of China (NPC) for discussion. The first draft...
FDA Reducing Price of New Drugs Through Drug Competition Action Plan
The Theory At the American Society of Clinical Oncology (ASCO), FDA Commissioner Dr. Scott Gottlieb introduced the Drug Competition Action Plan, which aims to lower new drug pricing by increasing generic (alternative) drug competition in the pharmaceutical market....
China’s New Human Genetic Resources Policy
CHINA’S NEW HUMAN GENETIC RESOURCES POLICY New Regulation Underway On May 28, 2019, the Chinese government published new regulations on the management of Human Genetic Resources (HGRs). The main objective of the government is to observe all HGR- related activities,...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com